SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Idenix Pharmaceuticals (IDIX)
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
412 15 0 IDIX
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
137TRx was exactly flat week over week. JonRobohogs-3/22/2007
136Any updated data on Tyzeka NRx 3/9? Thank you!goseek2-3/21/2007
135IDIX News Flow in 2007 investorshub.comgoseek2-3/10/2007
1342/23: NRx: 59, TRx:92, market share: 3.1 and 1.4%.rkrw-3/5/2007
133<i>Notice the "lunch" typo?</i> As in: NM283 is slated foDewDiligence_on_SI-3/4/2007
132Notice the "lunch" typo? JonRobohogs-3/4/2007
131Yaron Werber’s bearish report dated 3/2/07 is an example of the kind of shoddy wDewDiligence_on_SI-3/4/2007
130Idenix Q&A by Subject @ Earnings Call - 2 March 2007 investorshub.comgoseek2-3/3/2007
129Thanks, that CC was way too early for us Westerners. I expected to see that $20tuck-3/2/2007
128<i>>No product revenue guidance? Not even a wide range?<</i> DewDiligence_on_SI-3/2/2007
127>>Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Restuck-3/2/2007
126>>SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patuck-3/2/2007
125SVR data from the NM283 phase-2b trial in the treatment-naïve setting shoulDewDiligence_on_SI-2/24/2007
124See iHub for further discussion on this topic: investorshub.comDewDiligence_on_SI-2/23/2007
123PJ just came out with a bearish report that is paraphrased in SeekingAlpha. See DewDiligence_on_SI-2/23/2007
122>>SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a tuck-2/23/2007
1212/9: 55 NRx, 83 TRx; 2.6% new, 1.2% total.rkrw-2/20/2007
120IHub Idenix ReadMeFirst Updated 11 Feb investorshub.comgoseek2-2/12/2007
119IHub ReadMeFirst Update - Idenix investorshub.comgoseek2-2/10/2007
118JP Sommadossi in the ML webcast (in progress) just reiterated the argument in inDewDiligence_on_SI-2/8/2007
117Correct on all counts.rkrw-2/5/2007
1161/26: 60 TRx, 41 NRx, share 2% new, 0.9% total. pls explain the headings? is igoseek2-2/5/2007
1151/26: 60 TRx, 41 NRx, share 2% new, 0.9% total. Numbers are so tiny, I'll rkrw-2/5/2007
114IHub Idenix ReadMeFirst updated... 3 Feb investorshub.com also listen to why Hgoseek2-2/4/2007
113HCV Report from Susquehanna: investorshub.comDewDiligence_on_SI-2/1/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News